NESS ZIONA, Israel, Feb. 8, 2018 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel. Attendees representing the consortium's partners from academia, government, and industry will discuss achievements towards development of a universal influenza vaccine, including the recent successful results of the Phase 2b clinical trial on BiondVax's universal flu vaccine candidate M-001. Also expected to attend will be representatives from the U.S. Department of Health and Human Services (HHS).
Dr. Ed Schmidt, Executive Manager of the UNISEC consortium, commented, "UNISEC is pleased to see the significant advancements we have enabled towards improved influenza vaccines. We are grateful to the EU FP7 for their financial support of UNISEC and previous consortia towards this important goal. I also wish to thank the consortium partners for their remarkable collaborative spirit and intensive work."
Dr. Ron Babecoff, BiondVax's CEO, noted, "The UNISEC consortium collaboration has been a significant factor in propelling BiondVax's universal flu vaccine towards our upcoming pivotal Phase 3 trial. We are proud to be part of the UNISEC consortium and honored to host this meeting in Jerusalem."
Babecoff continued, "Experts report that we are currently experiencing the worst flu season since the 2009 pandemic. There is wide consensus for the urgent need to develop a broadly protective and effective influenza vaccine. BiondVax continues to lead the global effort and hopes to be the first to bring to the world a multi-strain multi-season universal flu vaccine, as our pivotal clinical efficacy Phase 3 trial is starting later this year."
Research supporting UNISEC activities received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012.
About BiondVax Pharmaceuticals Ltd
BiondVax is an advanced clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. BiondVax is traded onNASDAQ: BVXV. Please visit www.biondvax.com.
Information regarding the UNISEC Consortium is available at www.unisecconsortium.eu.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome; the outcome of the Phase 3 trials; ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resource and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.
For further information, please contact:
SOURCE BiondVax Pharmaceuticals Ltd.